Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
OBJECTIVE
To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2 receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg.


METHODS
Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug.


RESULTS
The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg.


CONCLUSIONS
In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.
Yamagishi
Hatsushi
H
Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan. hatsushi@f2.dion.ne.jp
Koike
Tomoyuki
T
Ohara
Shuichi
S
Horii
Toru
T
Kikuchi
Ryousuke
R
Kobayashi
Shigeyuki
S
Abe
Yasuhiko
Y
Iijima
Katsunori
K
Imatani
Akira
A
Suzuki
Kaori
K
Hishinuma
Takanori
T
Goto
Junichi
J
Shimosegawa
Tooru
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000081:Acetamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism; D018592:Cross-Over Studies; D065731:Cytochrome P-450 CYP2C19; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005838:Genotype; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D006635:Histamine H2 Antagonists; D010880:Piperidines; D054328:Proton Pump Inhibitors; D011725:Pyridines; D064747:Lansoprazole; C076948:lafutidine; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19